CHICAGO — May 06, 2026 — GE HealthCare is proud to announce the availability of MIM ComboTherapy™ GYN HDR/EBRT,[ii] a solution designed to help clinicians plan and evaluate complex radiation therapy treatments for gynecologic cancers with enhanced precision and confidence.
Gynecologic cancers, including cervical and uterine cancers, are often treated using a combination of radiation therapy approaches – most commonly external beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy. While this combination can be highly effective, it also presents a significant clinical challenge: each treatment contributes to the total radiation dose a patient receives, and clinicians must carefully account for prior doses to safely and effectively plan subsequent therapy.
“For far too long, women’s health has not received the focused attention and innovation it deserves – now is the time to intentionally prioritize the unique health needs of women and girls at every stage of life,” shares Shari Manuel, Sales Vice President, U.S. and Canada Imaging, GE HealthCare. “That gap is especially evident in the treatment of gynecologic cancers, where clinicians have historically had to rely on approximations when evaluating cumulative radiation dose – limiting our ability to fully optimize care. Innovations like MIM ComboTherapy™ GYN HDR/EBRT represent an important step forward, offering a more complete, patient-specific view of dose distribution across therapies. By enabling more personalized, data-driven decision-making, these advances have the potential to improve both treatment outcomes and quality of life for women bravely fighting these cancers.”
Ad Statistics
Times Displayed: 4950
Times Visited: 14 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
GE HealthCare’s new MIM ComboTherapy™ GYN HDR/EBRT addresses this need by providing a comprehensive, visual and quantitative approach to dose summation across treatment modalities – helping enable clinicians to better understand how radiation doses from multiple therapies interact within the patient’s anatomy, and support more informed clinical decision-making.
At the core of the technology is advanced 3D dose summation, incorporating both biological effective dose (BED) and Equivalent Dose in 2 Gy fractions (EQD2), enabling clinicians to assess the biological impact of combined treatments more accurately. By clearly visualizing areas of highest dose accumulation – often referred to as “hotspots” – clinicians can more effectively evaluate treatment plans and optimize therapy delivery.
